Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health and voluntary insurance benefits; financial protection products; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE South Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2018, the company had approximately 17 million members in medical benefit plans, as well as approximately 6 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Industry, Sector and Symbol
Industry Hospital & medical service plans
Sub-IndustryManaged Health Care
SectorMedical
Phone502-580-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$56.91 billion
Profitability
Miscellaneous
Employees41,600
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Humana (NYSE:HUM) Frequently Asked Questions
What is Humana's stock symbol?
Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."
How often does Humana pay dividends? What is the dividend yield for Humana?
Humana announced a quarterly dividend on Friday, February 8th. Investors of record on Friday, March 29th will be paid a dividend of $0.55 per share on Friday, April 26th. This represents a $2.20 annualized dividend and a dividend yield of 0.79%. The ex-dividend date is Thursday, March 28th. This is a boost from Humana's previous quarterly dividend of $0.50. View Humana's Dividend History.
How will Humana's stock buyback program work?
Humana declared that its Board of Directors has authorized a share repurchase program on Friday, December 15th 2017, which allows the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its stock is undervalued.
How were Humana's earnings last quarter?
Humana Inc (NYSE:HUM) issued its earnings results on Wednesday, February, 6th. The insurance provider reported $2.65 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.53 by $0.12. The insurance provider earned $14.17 billion during the quarter, compared to the consensus estimate of $14.04 billion. Humana had a return on equity of 19.64% and a net margin of 2.96%. Humana's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business posted $2.06 earnings per share. View Humana's Earnings History.
When is Humana's next earnings date?
What guidance has Humana issued on next quarter's earnings?
Humana issued an update on its FY19 earnings guidance on Wednesday, February, 6th. The company provided earnings per share (EPS) guidance of $17.00-17.50 for the period, compared to the Thomson Reuters consensus estimate of $17.48. Humana also updated its FY 2019 guidance to $17.00-17.50 EPS.
What price target have analysts set for HUM?
16 Wall Street analysts have issued 1 year target prices for Humana's stock. Their predictions range from $275.02 to $418.00. On average, they anticipate Humana's share price to reach $357.0013 in the next twelve months. This suggests a possible upside of 27.9% from the stock's current price. View Analyst Price Targets for Humana.
What is the consensus analysts' recommendation for Humana?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Humana.
What are Wall Street analysts saying about Humana stock?
Here are some recent quotes from research analysts about Humana stock:
- 1. According to Zacks Investment Research, "Humana’s fourth-quarter operating earnings per share of $2.65 beat the Zacks Consensus Estimate by 4.7% and also improved 28.6% year over year. This upside can primarily be attributed to Medicare Advantage membership growth and significant operating efficiency. The company is well-poised for growth on the back of its strong Medicare business. Its top line has been witnessing an uptrend for the past several years. Acquisitions and dispositions made by the company have also led to business growth over the last few quarters. However, its shares have underperformed its industry’s in a year’s time. Its rising level of expenses since 2010 persistently weighs on the bottom line. The company expects high benefit expenses which will lead to an overall increase in operating expenses going forward. " (2/8/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating on HUM shares and maintain our 12-month price target of $325. After the market close on the company reaffirmed its 2018 EPS guidance. The company also provided updated 2019 membership metrics. Given the update, we are increasing our 2019 revenue and EPS estimates. The company had previously indicated that it expected 2019 adjusted EPS to grow above its stated long-term goal of 11-15%. With its filing on Wednesday, the company did not comment on 2019 EPS guidance, but will provide detailed 2019 financial guidance when it reports 4Q18 and year-end 2018 results on Wednesday, February 6, 2019." (1/2/2019)
Has Humana been receiving favorable news coverage?
Press coverage about HUM stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Humana earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned press coverage about the insurance provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
Who are some of Humana's key competitors?
What other stocks do shareholders of Humana own?
Who are Humana's key executives?
Humana's management team includes the folowing people:
- Mr. Bruce Dale Broussard, Pres, CEO & Director (Age 57)
- Mr. Brian Andrew Kane, Chief Financial Officer (Age 46)
- Mr. Timothy S. Huval, Chief HR Officer (Age 53)
- Ms. Jody L. Bilney, Chief Consumer Officer (Age 58)
- Dr. William Kevin Fleming Pharm.D., PharmD, RPh, Segment Pres of Healthcare Services (Age 51)
Who are Humana's major shareholders?
Humana's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (9.10%), BlackRock Inc. (8.75%), Bank of America Corp DE (1.68%), Newport Trust Co (1.29%), Geode Capital Management LLC (1.31%) and Northern Trust Corp (1.26%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Christopher H Hunter, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming. View Institutional Ownership Trends for Humana.
Which major investors are selling Humana stock?
HUM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Orbimed Advisors LLC, Bank of Montreal Can, Bank of New York Mellon Corp, Robeco Institutional Asset Management B.V., Nuveen Asset Management LLC, Mackay Shields LLC and Acadian Asset Management LLC. Company insiders that have sold Humana company stock in the last year include Bruce D Broussard, Christopher H Hunter, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, Jody L Bilney, Roy A Beveridge, Timothy Alan Wheatley and William Kevin Fleming. View Insider Buying and Selling for Humana.
Which major investors are buying Humana stock?
HUM stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Millennium Management LLC, Ceredex Value Advisors LLC, Geode Capital Management LLC, Boston Partners, AMF Pensionsforsakring AB, California Public Employees Retirement System and Northern Trust Corp. View Insider Buying and Selling for Humana.
How do I buy shares of Humana?
Shares of HUM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Humana's stock price today?
One share of HUM stock can currently be purchased for approximately $279.05.
How big of a company is Humana?
Humana has a market capitalization of $37.85 billion and generates $56.91 billion in revenue each year. The insurance provider earns $1.68 billion in net income (profit) each year or $14.55 on an earnings per share basis. Humana employs 41,600 workers across the globe.
What is Humana's official website?
How can I contact Humana?
Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The insurance provider can be reached via phone at 502-580-1000 or via email at [email protected]
MarketBeat Community Rating for Humana (NYSE HUM)
MarketBeat's community ratings are surveys of what our community members think about Humana and other stocks. Vote "Outperform" if you believe HUM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HUM will underperform the S&P 500 over the long term. You may vote once every thirty days.
